Arcturus Therapeutics Holdings (ARCT) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Arcturus Therapeutics Holdings (ARCT) is Neutral.

The composite score behind that read is -0.01, weighing +0.33 of bullish evidence against -0.33 bearish.

Arcturus Therapeutics Holdings last closed at $13.74, +6.76% on the session.

Against the IVW growth benchmark the position is +5.96% over the forecast window.

The read is built from 15 underlying insights — 1 bullish and 14 bearish.

Agreement across those insights is 93%.

20 graded predictions for ARCT so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Arcturus Therapeutics Holdings in the 19th percentile on return on equity, where 100 is best.

Arcturus Therapeutics Holdings is classified under Health Care / Biotechnology, with a market capitalisation of $365.80M.

StockMap tracks Arcturus Therapeutics Holdings as the 201st largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Arcturus Therapeutics Holdings ranks 105th of 381 in the group, against a group median of -0.08.